Neuroblastoma takes the lives of more children under five than any other cancer. Help us fund new research to find a cure within our lifetime and save toddlers' lives. Read more
In 2022, we announced the winners of our most recent grants round. Two exceptional scientists will lead studies to develop tailored treatments to improve outcomes for children with neuroblastoma. Read more
Supported by an experienced group facilitator, this virtual group is your safe space to meet and talk to other parents who have a little hero diagnosed with neuroblastoma childhood cancer. Read more
Neuroblastoma Australia funds and supports innovative research with real potential to change survival rates. Our 2024 Grant Round has now closed. The next grant round will be in 2026 Read more
Purpose in every purchase. Shop beautiful baby and toddler essentials that make a difference. 100% profits raised support vital neuroblastoma research to change the future for children diagnosed with this devastating childhood cancer. Read more
One in two children with aggressive neuroblastoma will not survive. Neuroblastoma is the number one toddler cancer. We need your help to find effective treatments. Donate today to support world class Australian research into developing less toxic, more effective treatments, with the ultimate goal of finding a cure. Donate as an individual or business and receive a tax-deductible receipt for all donations over $2. Read more
In September, during Childhood Cancer Awareness Month, Trent Robertson completed an extraordinary challenge to support children battling neuroblastoma. Covering 2,000km in just 30 days, Trent ran and cycled from Parkdale, Victoria, to Noosa Heads Surf Life Saving Club in Queensland, raising over $100,000 for life-saving research. Read more
Grant recipient 2024. Received: $150,000. Research project: Enhancing Immunotherapy in High-Risk Neuroblastoma. Read more
Grant recipient 2024. Received: $150,000. Research project: Targeting an RNA Methyltransferase to Treat Neuroblastoma. Read more
Grant recipient 2024. Received: $150,000. Research Project: Developing Humanised Immunocompetent Mouse Models of High-Risk Neuroblastoma. Read more
Grant recipient 2023. Received: $175,000. Research project: Improving treatment outcomes using nanoparticle therapy. Read more
Grant recipient 2023. Received: $175,000. Research project: Identify key genetic features that allow resistance to chemotherapy Read more
Grant recipient 2021. Received: $172,000. Research project: Chromatin and Mitochondria Directed Therapy. Read more
Grant recipient 2021. Received: $125,000. Research project: High-risk neuroblastoma with TERT oncogene. Read more
Grant recipient 2020. Received: $125,000. Research project: TERT oncogene rearrangement Read more
Grant recipient 2021. Received: $175,000. Research project: Venetoclax combination study. Read more
Grant recipient 2020. Received: $125,000. Research project: Using MYC inhibitors to potentiate CART cell therapy for neuroblastoma. Read more
Recipient : Assoc. Professor Liu Institute: Children's Cancer Institute Funding: $150,000 Read more
Recipient : Dr. Emmy Dolman Institute: Children's Cancer Institute Funding: $150,000 Read more
Recipient : Dr. Toby Trahair Institute: Children's Cancer Institute Funding: $150,000 Read more
Grant recipient 2020. Received: $125,000. Research project: Find a novel therapy for high-risk neuroblastoma. Read more
Grant recipient 2019. Received: $150,000. Research project: Clinical trial for CBL137 single agent clinical trials. Read more
Grant recipient 2018. Received: $29,300. Research project: Research into radionuclide therapy alone and in combination with other therapies. Read more
Grant recipient 2018. Received: $558,180 from 2010 to 2019 Research project: Pre-clinical research for CBL137 in combination with other targeted therapies, led by Professors Michelle Haber, Murray Norris and Glenn Marshall. Read more
Grant recipient 2019. Received: $42,930. Research project: Improving the long-term health of Australian childhood cancer survivors. Read more
Grant recipient 2018. Received: $558,180 from 2010 to 2019. Research project: Pre-clinical research for CBL137 in combination with other targeted therapies, led by Professors Michelle Haber, Murray Norris and Glenn Marshall. Read more